Related Experiment Video
Updated: Mar 28, 2026

Characterizing DNA Repair Processes at Transient and Long-lasting Double-strand DNA Breaks by Immunofluorescence Microscopy
Published on: June 8, 2018
The BRCA1-A complex restricts replication fork reversal-dependent DNA repair in ATM deficient cells
Arindam Datta1, Jessica Jackson2, Yaroslav I Morozov1
1Department of Cancer Biology, Penn Center for Genome Integrity, Basser Center for BRCA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Abstract:
Ataxia Telangiectasia Mutated (ATM) kinase deficiency results in cancer susceptibility and drug sensitivity. Deficiency in either the BRCA1 interacting A complex or XRCC4/Ligase 4 confers resistance to Topoisomerase I or PARP1 inhibitors in ATM-deficient cells. This suggests that BRCA1-A directs toxicity to fork-damaging agents in ATM mutated cells vis-à-vis illegitimate end-joining. Here, we show that ATM inhibition triggers combined SUMO and ubiquitin mediated BRCA1-A damaged fork recognition to restrict end-resection and cause Topoisomerase I inhibitor hypersensitivity. BRCA1-A deficient cells display elevated chromatin accessibility and nuclease activity at damaged forks, coupled with restored resection and drug resistance. Electron microscopy evidence demonstrates that ATM inhibition prevents replication fork reversal, which is restored by BRCA1-A loss to generate substrates for end resection. These findings reveal that BRCA1-A enforces a restrictive chromatin state to suppress the genesis of resection substrates, implicating fork reversal as a key determinant of chemotherapy response in ATM deficient cells.
Insights
Ataxia Telangiectasia Mutated (ATM) kinase deficiency causes cancer and drug sensitivity. Our study shows BRCA1-A complex loss restores drug resistance in ATM-deficient cells by enabling DNA repair pathways.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Ataxia Telangiectasia Mutated (ATM) kinase deficiency is linked to cancer susceptibility and heightened sensitivity to certain chemotherapies.
- The BRCA1-interacting A (BRCA1-A) complex and the XRCC4/Ligase 4 complex play roles in DNA repair pathways, influencing drug resistance in ATM-deficient cells.
Purpose of the Study:
- To investigate the role of ATM inhibition and the BRCA1-A complex in DNA damage response and drug sensitivity.
- To elucidate the mechanisms by which BRCA1-A influences the recognition of damaged replication forks and subsequent DNA repair.
Main Methods:
- Utilized ATM inhibition models in cancer cells.
- Investigated SUMO and ubiquitin-mediated signaling at damaged replication forks.
- Assessed chromatin accessibility, nuclease activity, and DNA end-resection.
- Employed electron microscopy to visualize replication fork dynamics.
Main Results:
- ATM inhibition triggers SUMO/ubiquitin-mediated BRCA1-A recognition of damaged forks, restricting end-resection and increasing Topoisomerase I inhibitor sensitivity.
- BRCA1-A deficient cells exhibit increased chromatin accessibility and nuclease activity, leading to restored resection and drug resistance.
- ATM inhibition blocks replication fork reversal, a process restored by BRCA1-A loss, generating substrates for end resection.
Conclusions:
- BRCA1-A enforces a restrictive chromatin state that prevents the formation of DNA end-resection substrates.
- Replication fork reversal is a critical determinant of chemotherapy response in ATM-deficient cells.
- Targeting the BRCA1-A pathway could offer new therapeutic strategies for ATM-deficient cancers.
Related Concept Videos
Restarting Stalled Replication Forks
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Homologous Recombination
The DNA Replication Fork
The DNA Replication Fork

